Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4.
Cyclophosphamide
Cytochrome P450
Hepatocyte
Liver metabolism
Toxicity
γH2AX foci
Journal
Toxicology
ISSN: 1879-3185
Titre abrégé: Toxicology
Pays: Ireland
ID NLM: 0361055
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
04
07
2018
revised:
23
11
2018
accepted:
26
11
2018
pubmed:
1
12
2018
medline:
24
5
2019
entrez:
1
12
2018
Statut:
ppublish
Résumé
Preclinical drug safety assessment includes in vitro studies with physiologically relevant cell cultures. As an in vitro system for hepatic toxicology testing, we have been generating cell clones of human hepatoblastoma cell line HepG2 by lentiviral transduction of phase I cytochrome P450 (CYP) enzymes. Here, we present a stable CYP2C19-overexpressing HepG2 cell clone (HepG2-2C19 C1) showing an enzyme activity of approximately 82 pmol x min
Identifiants
pubmed: 30500380
pii: S0300-483X(18)30620-6
doi: 10.1016/j.tox.2018.11.008
pii:
doi:
Substances chimiques
Acrolein
7864XYD3JJ
Cyclophosphamide
8N3DW7272P
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Cytochrome P-450 CYP3A
EC 1.14.14.1
CYP3A4 protein, human
EC 1.14.14.55
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-47Informations de copyright
Copyright © 2018. Published by Elsevier B.V.